Drugs / 18F-fluorodeoxythymidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01207895 | Mar 2010 → Dec 2012 | rectal cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-fluorodeoxythymidine | “an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment” NCT01207895 ↗ |
| Known as | [18F]-FLT | “an imaging agent called 18F-fluorodeoxythymidine(\[18F\]-FLT) will allow investigators to measure how well tumor(s) respond to treatment” NCT01207895 ↗ |
| Modality | Diagnostic / imaging agent | “an imaging agent called 18F-fluorodeoxythymidine” NCT01207895 ↗ |